Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C21H26N2O2S2.C6H6O3S |
| Molecular Weight | 560.748 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)C1=CC=CC=C1.CN2CCCCC2CCN3C4=CC(=CC=C4SC5=C3C=CC=C5)S(C)(=O)=O
InChI
InChIKey=POTAUFBGHYTSIE-UHFFFAOYSA-N
InChI=1S/C21H26N2O2S2.C6H6O3S/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)26-21-11-10-17(15-19(21)23)27(2,24)25;7-10(8,9)6-4-2-1-3-5-6/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3;1-5H,(H,7,8,9)
| Molecular Formula | C6H6O3S |
| Molecular Weight | 158.175 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C21H26N2O2S2 |
| Molecular Weight | 402.573 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Sulforidazine (Imagotan (Sandoz); Inofal (Sandoz)) is a typical piperidine-type phenothiazine antipsychotic agent. It is dopamine receptor blocker. Being the second active metabolite of thioridazine (converted from mesoridazine), Sulforidazine is significantly more potent than the parent drug.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. | 2001 Dec |
|
| Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. | 2003 May |
|
| Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. | 2003 Sep-Oct |
|
| No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. | 2007 May |
|
| Factors affecting drug concentrations and QT interval during thioridazine therapy. | 2007 Nov |
Sample Use Guides
The metabolism of sulforidazine was studied in female dogs and adult male humans after oral administration of 37.5 mg and 25.0 mg, respectively.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: The electrically evoked overflow of dopamine (DA) from perfused rabbit striatal slices was used to assess the relative functional potencies of thioridazine, a phenothiazine antipsychotic agent, and two of its major metabolites, mesoridazine (thioridazine-2-sulfoxide) and sulforidazine (thioridazine-2-sulfone).
Mesoridazine and sulforidazine likewise produced only small increases (5-20%) in evoked overflow of DA from slices stimulated at 0.3 Hz. At this frequency of stimulation, apomorphine (30 nM) inhibited the overflow of DA by 71.4 +/- 8.43% (n = 40). All three drugs antagonized, in a concentration-dependent fashion, the inhibitory effect of apomorphine (30 nM) on electrically evoked DA release at 0.3 Hz. The IC50 for thioridazine for antagonizing the effect of apomorphine was 130 nM, whereas that for mesoridazine was 14.4 nM and for sulforidazine was 6.1 nM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:51:58 GMT 2023
by
admin
on
Fri Dec 15 18:51:58 GMT 2023
|
| Record UNII |
7L0AV9G67Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23255-94-9
Created by
admin on Fri Dec 15 18:51:58 GMT 2023 , Edited by admin on Fri Dec 15 18:51:58 GMT 2023
|
PRIMARY | |||
|
7L0AV9G67Z
Created by
admin on Fri Dec 15 18:51:58 GMT 2023 , Edited by admin on Fri Dec 15 18:51:58 GMT 2023
|
PRIMARY | |||
|
23619868
Created by
admin on Fri Dec 15 18:51:58 GMT 2023 , Edited by admin on Fri Dec 15 18:51:58 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |